Trial Profile
A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; PVX 410 (Primary) ; Poly ICLC
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics
- 13 Nov 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 13 Nov 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 21 Dec 2022 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2023.